Targent Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $2.72M

Targent General Information

Description

Developer of cytotoxic drugs for treatment of advanced prostate cancer. The company develops therapeutic drugs from archived compounds for oncology patients for the treatment of prostate cancer.

Contact Information

Website
www.targent.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Targent 181 Cherry Valley Road
  • Princeton, NJ 08540
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Spectrum Pharmaceuticals
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Targent 181 Cherry Valley Road
  • Princeton, NJ 08540
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Targent Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 20-Apr-2006 $2.72M Completed Generating Revenue
1. Early Stage VC Completed Startup
To view Targent’s complete valuation and funding history, request access »

Targent Patents

  • 13

    Total Documents Applications and Grants

  • Total Patents Families

  • 1

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

Targent Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2020219566-A1 Combination therapeutic regimens with 1,6-dibromo-1,6-dideoxy-dulcitol Inactive 24-Apr-2019
CA-2989420-A1 New crystalline polymorphs of 1,6-dibromo-1,6-dideoxy-dulcitol Inactive 16-Jun-2015
EP-3310746-A1 New crystalline polymorphs of 1,6-dibromo-1,6-dideoxy-dulcitol Inactive 16-Jun-2015
EP-3981758-A1 New crystalline polymorphs of 1,6-dibromo-1,6-dideoxy-dulcitol Inactive 16-Jun-2015
WO-2016205299-A1 New crystalline polymorphs of 1,6-dibromo-1,6-dideoxy-dulcitol Inactive 16-Jun-2015 C07C31/42
To view Targent’s complete patent history, request access »

Targent Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Johnston Associates Venture Capital Minority
To view Targent’s complete investors history, request access »

Ready to get started?

Request a free trial

Targent FAQs

  • When was Targent founded?

    Targent was founded in 2001.

  • Where is Targent headquartered?

    Targent is headquartered in Princeton, NJ.

  • What industry is Targent in?

    Targent’s primary industry is Drug Discovery.

  • Is Targent a private or public company?

    Targent is a Private company.

  • What is the current valuation of Targent?

    The current valuation of Targent is .

  • What is Targent’s current revenue?

    The current revenue for Targent is .

  • Who are Targent’s investors?

    Johnston Associates has invested in Targent.

  • When was Targent acquired?

    Targent was acquired on 20-Apr-2006.

  • Who acquired Targent?

    Targent was acquired by Spectrum Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process